BAUDETTE, Minn., June 27, 2018 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the
launch of Cholestyramine for Oral Suspension USP, 4g/dose, in
cans. The current annual U.S. market for this product is
approximately $22 million, according
to Iqvia/IMS Health.
Arthur S. Przybyl, ANI's
President and CEO stated, "This launch is the tenth product that
ANI has successfully completed a manufacturing site transfer and
recommercialized. These product launches are from previously
discontinued ANDA's that ANI has acquired over the last several
years. We continue to commit product development resources in
order to launch additional discontinued ANDA's that we believe can
provide us with meaningful cash flow once
re-commercialized."
About Cholestyramine for Oral Suspension USP
Cholestyramine for Oral Suspension USP is indicated as
adjunctive therapy to diet for the reduction of elevated serum
cholesterol in patients with primary hypercholesterolemia (elevated
low density lipoprotein [LDL] cholesterol) who do not respond
adequately to diet.
Cholestyramine for Oral Suspension USP may be useful to lower
LDL cholesterol in patients who also have hypertriglyceridemia, but
it is not indicated where hypertriglyceridemia is the abnormality
of most concern.
Cholestyramine for Oral Suspension USP monotherapy has been
demonstrated to retard the rate of progression and increase the
rate of regression of coronary atherosclerosis.
Cholestyramine for Oral Suspension USP is also indicated for the
relief of pruritus associated with partial biliary
obstruction.
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an
integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription
pharmaceuticals. The Company's targeted areas of product
development currently include narcotics, oncolytics (anti-cancers),
hormones and steroids, and complex formulations involving extended
release and combination products. For more information, please
visit our website www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about price increases, the Company's future
operations, products financial position, operating results and
prospects , the Company's pipeline or potential markets therefor,
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "plans," "potential," "future," "believes,"
"intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Uncertainties and risks include,
but are not limited to, the risk that the Company may face with
respect to importing raw materials; increased competition;
acquisitions; contract manufacturing arrangements; delays or
failure in obtaining product approval from the U.S. Food and
Drug
Administration; general business and economic conditions; market
trends; products development; regulatory and other approvals and
marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange
Commission, including its most recent annual report on Form 10-K
and quarterly reports on Form 10-Q, as well as its proxy statement.
All forward-looking statements in this news release speak only as
of the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
View original
content:http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-launch-of-cholestyramine-for-oral-suspension-usp-300672967.html
SOURCE ANI Pharmaceuticals, Inc.